Sorrento Therapeutics Inc (SRNE)

[dia76ca]

Latest version of Sorrento Therapeutics Boom List

1.Sorrento partner with Dyadic to licence DYAI-100 as a cheap alternative to other Vaccines and reveal it elicits strong immune responses against Covid and multiple major variants of concern

2.Covistix approved in Mexico and Brazil and EU- First order of 25m tests shipped July 21. 5m kits sold Nov 21- Expecting large revenues, Canada and US to follow. Ji confirmed they can make 50 million tests per month and orders are waiting. www.covistix.com appeared on a live website and looks ready for US sales. Independent study shows Covistix to have superior sensitivity to leading brands. Listed for sale on Mex website $8 US per test. 10Q Shows lease on massive distribution center.

3.COVISHIELD Ramping up development in partnership with Mount Sinai.

4.COVI-MSC- Phase 1b tests complete 10/10 patients recovered from mechanical ventilation and leaving hospital after a week!!! Phase 2 PIVOTAL Approved in Brazil May 2021

5.Fortune Bio (Sorrento Manufacturer in China) Confirmed Covi-Stix being made with CE approval certificate. This and Respi-Stix listed for sale. http://www.fortunetest.com/. Setting up manufacturing in US and moving Fortune Bio Technology to fulfil this. Confirmed in a job description and shipping forms.

6.RESPI-STIX combination test for viruses including Covid, Flu A and B

7.Covi-Trace application submitted- Brunswick mentioned they are submitting a low nasal swab version

8.DARPA funding of at least $34m to bring STI 2020 to the end of P2 trials and beyond. Three phase 2 trials of COVI-AMG being delivered to 1000 patients. STI2020 is a refined version of 1499 with increased potency and requires smaller dosage. AKA Covi-Drops

9.Multi-year deal with the U.S. Naval Medical Research Unit initially using Covi-Stix, Track, Drops and AMG announced June 2021” This will rapidly and efficiently deploy our products in all parts of the world”

10.Abivertinib, Cures Covid at late stages. P2 Complete - impressive readout but PR bungled. P3 Imminent

11.Covi-Drops STI2099 (Refined version of 1499) nasal antibody spray. PH2 trial in the UK 350 Patients dosing started. PH2 in the US also underway recruiting 1800 patients.

12.Sorrento Therapeutics entered into an Exclusive Licensing Term Sheet with Aardvark Therapeutics to Acquire Its ARD-301 For the Treatment of Chronic Pain, Fibromyalgia, and Chronic Long Haul Covid Syndrome- Ph2 already approved to proceed. Also ARD-101 collaboration on obesity drug Ph2 Q4 ‘21

13.Testing Lab approved in California for Covid (will speed up in house testing and provide source of revenue)

14. Covid programs in progress with strong potential- T-VIVIA-19 combination vaccines in development

15.ACEA owned- full ownership of Abivertinib, multiple pipeline additions and a large manufacturing facility.

16.Kelun, Phase I Study of A166, for Breast Cancers released positive results Jun 21. (Licence)

17.Sofusa DoseConnect multiple Ph1b trial extended Aug 21 to test lower dosage as current dose showed “quite remarkable improvements” after 10 weeks. Drug already approved – this is all about the delivery. Multiple drugs can be dosed this way and used to extend patents! June 2021 1b trial delivery patients with Melanoma- first of many with Mayo C.

18.Manufacturing of testing to be brought in house leveraging Bioserve potentially instead of ANP acquisition

19.Lee’s Pharmaceutical Anti-PD-L1 Antibody Socazolimab, licensed from Sorrento Breakthrough designation. Multiple P3 trials underway for approval in China.

20.Sorrento Partner Mabpharm has Received Marketing Approval in China for Infliximab Biobetter. Sorrento holds licence for rest of world and working with FDA on equivalence. $4.2 billion global market.

21. Last year we acquired multiple companies. We own 18% of Celulatory

22. STI-6643 Ph1 Trial approved for multiple cancer type treatments “Basket Trial”

23. Subsidiary Company - ADNAB, Inc. - to Develop and Commercialize ADNAB™ Platform Products for Haematological Malignancies and Solid Tumours Based on an Exclusive Technology License from the Mayo Clinic- Multiple IND’s in 2021- April 2021 FDA Clearance to Proceed with Phase 2 Study for Sti-3031, an Anti-Pd-L1 Antibody, for Advanced Urothelial Carcinoma

24. Institutions buying in and own 26% of stock: BlackRock 6.4% Vanguard 4.5% and State Street 3.3%

25. Multiple cancer and pain relief plays which triggered BO offers excess of $7 in 2019 before Covid started

26. One drug approved (ZTildo) and sales are growing massively (33 million more potential patients Aug 21)

27. Immunity Bio and NK merger completed resulting in us owning 8.19m shares in $IBRX. PSS is chairman of NK. Expecting $1bn in stock or cash as part of the settlement for Cynviloq case Post arbitration set for November 30. We sold for over $100m

28. Four analysts have us at $20-35 which is very conservative.

29. CEO only gets share options if he maintains SP above $17-130 for six consecutive months

30. We have been heavily shorted due to a scam by Hindenburg (top 30 most shorted) and perhaps PSS manipulating the price. We are poised for a massive short squeeze.

31. SP-102 Ph3 trial fully enrolled - first FDA approved epidural steroid product for the treatment of sciatica by Jan 2022 Top line results due. Ph2 saw 100% of patients with at least 50% pain improvement.

32. RTX Ph3- Non Opioid treatment for Arthritis/Cancer pain, trial approved Q4 2021. P1b results v positive

33. NDA in China for Abivertinib for NSCLC expecting the same in the US this year

34. Significant recruitment in manufacturing roles and warehouse facilities.

35. July 2021, Sorrento lease a massive new facility next to HQ. Clear indication of manufacturing contracts

36. At WuXi HF Ji mentioned antibody cocktail will target all Covid and potentially ALL Viruses including HIV

37. Speculation of buyout growing credence with multiple products moving towards approval